Corteva (CTVA) Valuation Check After Resurrect Bio Funding And Recent Share Price Momentum

Simply Wall St.02-18

Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612414077?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/2023000-choice1-main-header/1585186651478","is_english":true,"pubTime":"2026-02-18 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612414077","market":"nz","top_or_hot":-1,"title":"Corteva (CTVA) Valuation Check After Resurrect Bio Funding And Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-ctva/corteva/news/corteva-ctva-valuation-check-after-resurrect-bio-funding-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corteva (CTVA) Valuation Check After Resurrect Bio Funding And Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorteva (CTVA) Valuation Check After Resurrect Bio Funding And Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-18 17:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/materials/nyse-ctva/corteva/news/corteva-ctva-valuation-check-after-resurrect-bio-funding-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-ctva/corteva/news/corteva-ctva-valuation-check-after-resurrect-bio-funding-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4093","symbol_name":"化肥与农用药剂","start_time":0,"source_url":"https://simplywall.st/stocks/us/materials/nyse-ctva/corteva/news/corteva-ctva-valuation-check-after-resurrect-bio-funding-and","article_id":"2612414077","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/2023000-choice1-main-header/1585186651478"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-ctva/corteva/news/corteva-ctva-valuation-check-after-resurrect-bio-funding-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612414077","pubTimestamp":1771406886,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits and potential commercial partnerships.\nSee our latest analysis for Corteva.\nAlongside the Resurrect Bio investment and a recently completed US$569.98 million share buyback, Corteva’s 30 day share price return of 8.49% and 90 day share price return of 16.81% suggest momentum has been building,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4093":"化肥与农用药剂","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","BK4588":"碎股","LU0612318385.USD":"BGF NATURAL RESOURCES \"A2\" (USD) ACC","LU0345780950.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","LU0654597011.USD":"BGF NATURAL RESOURCES \"A4G\" (USD) INC","LU0612318971.USD":"BGF NATURAL RESOURCES \"A5G\" (USD) INC","CTVA":"Corteva, Inc.","LU2211817866.USD":"Allianz Food Security AT Acc USD","LU0345781412.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) INC","LU0300736062.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","SG9999002521.SGD":"United Global Resources A Acc SGD","LU0630314457.HKD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (HKD) ACC","LU0300736492.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) INC","LU1430597077.USD":"BGF NATURAL RESOURCES \"A\" (USD) INC"},"translate_title":"复活生物融资和近期股价势头后的Corteva(CTVA)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTVA":1.5},"content_text":"Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits and potential commercial partnerships. See our latest analysis for Corteva. Alongside the Resurrect Bio investment and a recently completed US$569.98 million share buyback, Corteva’s 30 day share price return of 8.49% and 90 day share price return of 16.81% suggest momentum has been building, supported by a 1 year total shareholder return of 18.41%. If this kind of dealmaking has your attention, it could be a good moment to look at other agriculture linked opportunities through our list of 7 top copper producer stocks as a potential starting point. Solid recent returns, a US$82.76 price target that sits above the current US$75.55 share price, and an intrinsic value estimate implying a premium all raise the same question: is Corteva still a buy or is future growth already priced in? AdvertisementMost Popular Narrative: 7.9% Undervalued With Corteva closing at $75.55 against a widely followed fair value estimate of $82.05, the current setup reflects analyst expectations on growth, margins, and required returns.  Advancements in Corteva's innovation pipeline, including premium trait launches (Vorceed, PowerCore), expansion of biological products, and gene editing, enable premium pricing, secure market share, and improve product mix, translating into higher gross margins and earnings growth.  Read the complete narrative. Curious what earnings path and revenue mix could justify that higher fair value with a lower discount rate and richer future P/E multiple? The narrative leans on a very specific blend of margin expansion, steady top line growth, and capital returns that go well beyond a simple crop cycle story. Result: Fair Value of $82.05 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story could change quickly if pricing pressure in Crop Protection or tighter environmental rules begin to weigh on margins and on assumptions about long term demand. Find out about the key risks to this Corteva narrative. Another View: Premium Price Tag On Earnings There is a twist once you look at Corteva through its P/E. The shares trade on 42.6x earnings, compared with 15.8x for peers and 26.8x for the wider US Chemicals industry, while our fair ratio sits at 28.3x. That gap suggests you are paying a clear premium, so you need to decide whether Corteva’s story really justifies it. See what the numbers say about this price — find out in our valuation breakdown. NYSE:CTVA P/E Ratio as at Feb 2026Next Steps If this mix of potential and questions around Corteva resonates with you, take a closer look now and weigh up 2 key rewards and 1 important warning sign for yourself. Looking for more investment ideas? If Corteva has sharpened your focus on quality and price, do not stop here. Broaden your watchlist with a few targeted sets of opportunities.  Target value by reviewing 56 high quality undervalued stocks that pair stronger fundamentals with share prices that sit below our fair value estimates. Strengthen your income stream with 13 dividend fortresses that combine higher yields with an emphasis on payment stability. Protect your capital by scanning 80 resilient stocks with low risk scores that our model scores as more resilient on balance sheet and risk factors.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612414077","isCrawlerRequest":true}